167 related articles for article (PubMed ID: 10451217)
1. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.
Fox J; Lowe SH; Conklin RL; Nemeth EF
Endocrine; 1999 Apr; 10(2):97-103. PubMed ID: 10451217
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.
Wada M; Nagano N; Furuya Y; Chin J; Nemeth EF; Fox J
Kidney Int; 2000 Jan; 57(1):50-8. PubMed ID: 10620187
[TBL] [Abstract][Full Text] [Related]
3. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
4. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
5. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
Antonsen JE; Sherrard DJ; Andress DL
Kidney Int; 1998 Jan; 53(1):223-7. PubMed ID: 9453023
[TBL] [Abstract][Full Text] [Related]
6. NPS R-568 halts or reverses osteitis fibrosa in uremic rats.
Wada M; Ishii H; Furuya Y; Fox J; Nemeth EF; Nagano N
Kidney Int; 1998 Feb; 53(2):448-53. PubMed ID: 9461105
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
8. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.
Chin JI; Miller SC; Wada M; Nagano N; Nemeth EF; Fox J
J Am Soc Nephrol; 2000 May; 11(5):903-911. PubMed ID: 10770968
[TBL] [Abstract][Full Text] [Related]
9. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
Ishii H; Wada M; Furuya Y; Nagano N; Nemeth EF; Fox J
Bone; 2000 Feb; 26(2):175-82. PubMed ID: 10678413
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
11. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.
Fox J; Lowe SH; Petty BA; Nemeth EF
J Pharmacol Exp Ther; 1999 Aug; 290(2):473-9. PubMed ID: 10411552
[TBL] [Abstract][Full Text] [Related]
12. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
Rybczyńska A; Hoppe A
Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
[TBL] [Abstract][Full Text] [Related]
13. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
[TBL] [Abstract][Full Text] [Related]
14. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats.
Fox J; Lowe SH; Conklin RL; Petty BA; Nemeth EF
J Pharmacol Exp Ther; 1999 Aug; 290(2):480-6. PubMed ID: 10411553
[TBL] [Abstract][Full Text] [Related]
16. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.
Wada M; Furuya Y; Sakiyama J; Kobayashi N; Miyata S; Ishii H; Nagano N
J Clin Invest; 1997 Dec; 100(12):2977-83. PubMed ID: 9399943
[TBL] [Abstract][Full Text] [Related]
17. Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slows the rate of bone loss but does not increase bone mass in ovariectomized rats.
Miller MA; Fox J
Bone; 2000 Oct; 27(4):511-9. PubMed ID: 11033446
[TBL] [Abstract][Full Text] [Related]
18. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics with potent and selective activity on the parathyroid calcium receptor.
Nemeth EF; Steffey ME; Hammerland LG; Hung BC; Van Wagenen BC; DelMar EG; Balandrin MF
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):4040-5. PubMed ID: 9520489
[TBL] [Abstract][Full Text] [Related]
20. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
